Cargando…
Macular Hole Progression following Ocriplasmin Intravitreal Injection
Ocriplasmin is a protease which has been approved for the treatment of symptomatic vitreomacular adhesion (VMA). A 63-year-old presented with blurred vision in the left eye and a best corrected visual acuity of 6/18. Optical coherence tomography revealed VMA with an underlying macular hole and she s...
Autores principales: | Casswell, Edward, Fernandez-Sanz, Guillermo, Mitry, Danny, Luk, Sheila, Zakir, Rahila |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279821/ https://www.ncbi.nlm.nih.gov/pubmed/25580329 http://dx.doi.org/10.1155/2014/403461 |
Ejemplares similares
-
Myopic macular hole detachment associated with intravitreal ocriplasmin
por: Goh, Li Yen, et al.
Publicado: (2020) -
Multimodal imaging of macular subretinal deposits following intravitreal ocriplasmin injection
por: Chow, Nicholas, et al.
Publicado: (2018) -
Predicting the individual probability of macular hole closure following intravitreal ocriplasmin injections for vitreomacular traction release using baseline characteristics
por: Bertelmann, Thomas, et al.
Publicado: (2021) -
Intravitreal ocriplasmin for the treatment of vitreomacular traction and macular hole- A study of efficacy and safety based on NICE guidance
por: Muqit, Mahiul M. K., et al.
Publicado: (2018) -
Rhegmatogenous retinal detachment following intravitreal ocriplasmin
por: Madi, Haifa A., et al.
Publicado: (2016)